The Investigation of the Effect of Antibody Recruiting Molecules on Various Antigenic Markers (Cancer, Bacteria, Viruses): A Literature Review
Bibliographic record
Abstract
Introduction: Antibody recruiting molecules (ARMs) are small molecules with low molecular weight that guide endogenous antibodies towards both cancer and infectious cells, they facilitate the process of immune-mediated clearance. ARMs have two specific regions; a Target Binding Terminus interacts with disease biomarkers and the Antibody Binding Terminus, associated with endogenous antibodies. These modules are linked together by a tunable linker region bridging the endogenous antibody and the infected cell. ARMS can be used for a broad range of therapeutic applications, especially for its use against cancer, bacterial, and viral infections. ARMs serve a new potential treatment option over traditional therapies. Methods: To conduct our research, specific search terms were created, and relevant articles were screened on Covidence using an inclusion/exclusion criteria. The CASP and CRAAP checklist will be used for the quality assessment of the utilized sources. Results: ARMs treatment is a novel pathway which can treat a wide range of diseases from cancer, bacteria, to viruses. ARMs clearly represent promising alternatives in antitumor immunotherapy over traditional methods. Discussion: One hurdle of using ARMs is that its effect on individuals might differ based on antibody concentrations, their affinities, isotypes etc. Due to the non-specific nature of ARMs, there’s a selectivity issue regarding binding to specific biomarkers or antigens. The use of non-covalent ARMs to target the highly expressed receptors on the tumor can sometimes lead to endocytosis during the binding process before the recruitment of antibodies. This can be potentially solved by adding covalent linkages in the ARMs molecular construct. This paper analyzes the limitations of utilizing ARMs as an effective means for immunotherapy and proposes potential avenues of improvement for greater efficacy. Conclusion: This paper will potentially advance pharmaceutical and immunotherapeutic interventions available for numerous cancers and infectious diseases.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.010 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.003 | 0.003 |
| Bibliometrics | 0.016 | 0.014 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.002 | 0.002 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.001 |
| Insufficient payload (model declined to judge) | 0.007 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".